Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges

T Adachi, AW El-Hattab, R Jain… - International journal of …, 2023 - mdpi.com
This document provides a comprehensive summary of evidence on the current situation of
rare diseases (RDs) globally and regionally, including conditions, practices, policies, and …

Being the pillar for children with rare diseases—a systematic review on parental quality of life

J Boettcher, M Boettcher, S Wiegand-Grefe… - International journal of …, 2021 - mdpi.com
Parents caring for children with rare diseases fear the long-term progression of the child's
disease. The current study aims to systematically investigate the quality of life (QoL) in …

A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries

M Czech, A Baran-Kooiker, K Atikeler… - Frontiers in public …, 2020 - frontiersin.org
Background: Despite international initiatives on collaboration within the field of rare
diseases, patient access to orphan medicinal products (OMPs) and healthcare services …

Rare disease emerging as a global public health priority

CCY Chung, Hong Kong Genome Project… - Frontiers in Public …, 2022 - frontiersin.org
The genomics revolution over the past three decades has led to great strides in rare disease
(RD) research, which presents a major shift in global policy landscape. While RDs are …

[HTML][HTML] Access and unmet needs of orphan drugs in 194 countries and 6 areas: a global policy review with content analysis

AYL Chan, VKY Chan, S Olsson, M Fan, M Jit, M Gong… - Value in Health, 2020 - Elsevier
Objectives Three hundred million people living with rare diseases worldwide are
disproportionately deprived of in-time diagnosis and treatment compared with other patients …

How to value orphan drugs? A review of European value assessment frameworks

A Blonda, Y Denier, I Huys, S Simoens - Frontiers in Pharmacology, 2021 - frontiersin.org
Background: Decision-makers have implemented a variety of value assessment frameworks
(VAFs) for orphan drugs in European jurisdictions, which has contributed to variations in …

Drug discovery and development in rare diseases: taking a closer look at the tafamidis story

A Burton, A Castaño, M Bruno, S Riley… - Drug design …, 2021 - Taylor & Francis
Rare diseases are increasingly recognized as a global public health priority. Governments
worldwide currently provide important incentives to stimulate the discovery and development …

Measuring what matters to individuals with Angelman syndrome and their families: development of a patient-centered disease concept model

T Willgoss, D Cassater, S Connor, ML Krishnan… - Child Psychiatry & …, 2021 - Springer
Angelman syndrome (AS) is a complex, heterogeneous, and life-long neurodevelopmental
disorder. Despite the considerable impact on individuals and caregivers, no disease …

A comprehensive review on the current status of CRISPR based clinical trials for rare diseases

AK Badwal, S Singh - International Journal of Biological Macromolecules, 2024 - Elsevier
A considerable fraction of population in the world suffers from rare diseases. Clustered
Regularly Interspaced Short Palindromic Repeats (CRISPR) and its related Cas proteins …

Improvements needed to support people living and working with a rare disease in Northern Ireland: current rare disease support perceived as inadequate

J McMullan, AL Crowe, C Bailie, K Moore… - Orphanet Journal of …, 2020 - Springer
Background Many people living and working with rare diseases describe consistent
difficulties accessing appropriate information and support. In this study an evaluation of the …